RxDoctor Payments Data

Jacqueline Selph, MD

Dermatology · Flat Rock, NCNPI 1609219039

Payments from drug & device makers

$4,097in general payments, 2019–2025

Across 191 payments — averaging $21.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$496
  • Sun Pharmaceutical Industries Inc.$486
  • Novartis$357
  • Regeneron Healthcare Solutions, Inc.$184
  • Amgen$173
  • plus $1K from 25 others

What the payments were for

  • Speaking & faculty fees$2636%
  • Food & beverage$3,73991%
  • Education$952%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,097 in reported general payments places this provider in the 60th percentile of 475 dermatology providers in North Carolina.

See all dermatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$834,226
Medicare patients
1,456
Services billed
9,507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab15$106,539
OtezlaApremilast13$73,894
Clobetasol Propionate128$5,970
Triamcinolone Acetonide196$2,303
Fluorouracil26$1,531
Metronidazole32$1,382
Doxycycline Monohydrate59$1,215
Ketoconazole85$966
Doxycycline Hyclate38$774
Tretinoin12$721
Clindamycin Phosphate27$616
ValacyclovirValacyclovir Hcl28$507
Mupirocin61$403
Gabapentin44$389
Imiquimod14$266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$173$73,89413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 475 dermatology providers in North Carolina.

Other dermatology in Flat Rock

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →